Trevena, Inc.

Third-quarter net loss was $7.9 million, or $0.57 per share, versus $15.3 million, or $2.24 per share, in the same period last year; management said the lower loss was largely due to cost savings implemented in 2022. The company ended the quarter with $35 million in cash and marketable securities and said this should fund operations into the third quarter of 2024. Forward-looking commentary focused on TRV045: Trevena is optimizing formulation work to improve bioavailability and reduce the food effect, while toxicology work is expected to be completed in the second half of 2024. Management also said it is continuing to pursue partnering and other opportunities for OLINVYK, TRV045, and other pipeline candidates, but did not provide revenue or EPS guidance.

Carrie Bourdow framed the quarter as one of significant milestones, led by positive TRV045 proof-of-concept results and continued progress toward next steps in pain and epilepsy. She said Trevena is actively planning to advance TRV045 either on its own or with a strategic partner, and highlighted that the company is having conversations with interested partners in both epilepsy and pain. Her tone was upbeat but pragmatic, especially on OLINVYK, which she said remains challenging in the U.S. market.

Barry Shin reported a third-quarter net loss of $7.9 million, or $0.57 per share, down from $15.3 million, or $2.24 per share, a year ago, attributing the improvement largely to cost savings from 2022. He said Trevena finished the quarter with $35 million in cash and marketable securities, which he believes funds operations into the third quarter of 2024. He also noted the $15 million received from the first commercial sale of OLINVYK in China under the R-Bridge Financing agreement and said the company continues to investigate partnering and other opportunities to add resources and shareholder value.

Analysts focused mainly on TRV045 partnering strategy, formulation optimization, and how the epilepsy program affects corporate development. Management said it is flexible on partnerships, is looking for the best way to advance TRV045, and sees interest from potential partners in both epilepsy and pain; it also said the NIH seizure-prevention data is not a gating item, but would strengthen the story. On formulation, Mark Demitrack said the company wants to reduce the food effect, improve dosing flexibility, and increase plasma-exposure headroom, while animal data show about a four- to five-fold brain-to-plasma ratio, supporting CNS penetration.